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A B S T R A C T
Rationale and objective: Although malignant tumors of the brain and central nervous system (CNS)
represent less than 3% of new cancer cases estimated worldwide, they cause signiﬁcant morbidity and in
the case of gliomas, the most common histological type, have a poor prognosis. We describe patterns and
trends in brain and CNS incidence and mortality in Central and South America.
Methods: We obtained regional- and national-level incidence data from 48 population-based cancer
registries in 13 countries and cancer deaths from the WHO mortality database for 18 countries. We
estimated world population age-standardized incidence rates (ASRs) and mortality rates (ASMRs) per
100,000 person-years, and present incidence by histological subtypes.
Results: In general, incidence rates were higher in males than in females. The highest incidence ASRs were
observed for Cuba (5.1 males, 3.6 females) in Central America, and for Brazil (6.4 males, 4.8 females) and
Uruguay (6.2 and 4.0) in South America. Mortality rates closely followed the pattern of incidence rates.
Argentina, Brazil and Chile showed increasing mortality trends, although these were not statistically
signiﬁcant. Glioma and unspeciﬁed tumors were the most common histological types, accounting for
55.4% and 32.8%, respectively. The proportion of microscopically veriﬁed diagnoses was 47–70% in most
countries.
Conclusion: Although incidence and mortality rates in general were low, some countries displayed high-
to intermediate-level incidence rates; under-reporting and under-ascertainment of cases could
contribute to the geographic variations observed. There is a need to improve both the ascertainment
of cases and the accuracy of histological diagnosis. Monitoring of brain and CNS cancers along with
etiological research remain priorities.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Malignant tumors of the brain and central nervous system
(CNS) include a group of complex and rare diseases comprising
more than 50 different pathological entities that are diverse in
terms of site, morphology, molecular biology, and clinical behavior$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).[1]. Given their localization, morbidity associated with either
malignant tumors (estimated to be around one third of all brain
tumors) or non-malignant tumors is signiﬁcant and often life-
threatening [2,3].
In 2012, brain and CNS cancers accounted for approximately
256,000 new cases annually, representing less than 3% of new
cancer cases estimated worldwide [4]. Their distribution varies
across the world, with the highest incidence rates occurring in
Australia, North America and northern European countries,
especially among white populations, and the lowest in Africa [4,5].
Epidemiological studies in different parts of the world have
shown that males have a higher risk of malignant brain and CNS
tumors than females [5–7]; in addition, a distinctive age
distribution pattern has been described with highest incidence
rates occurring among adults 60 years and older, children 0–4
years, and adolescents [6,8]. The distribution of histology-speciﬁc
types also varies by age. While gliomas are the most common. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
S142 M. Piñeros et al. / Cancer Epidemiology 44S (2016) S141–S149primary malignant brain tumors in adults and account for 70–80%
of all brain and CNS malignancies [6,9], in children the most
common histological types are pilocytic astrocytomas, medullo-
blastomas and germ-cell tumors [10].
Despite the low frequency of these tumors, incidence and
mortality rates of malignant brain and CNS cancers have shown
increasing trends in the last few decades in many countries,
including histology-speciﬁc trends, attributed mainly to the
increased availability of diagnostic imaging and specialized medical
care [6,11,12]. Mortality due to this malignancy has been reported as
increasing in Colombia and Brazil [13,14]. The 2012 Globocan
estimates indicate that in the Central and South America region,
brain and CNS cancers were the 11th cause of cancer morbidity and
mortality in 2012, with 26,000 new cancer cases and 19,000 deaths
[4]. Despite this information, a description of the burden of brain and
CNS tumors in Central and South America is still lacking, preventing
further predictions in a region where the overall cancer burden is
expected to increase by 50–60% by the year 2030 [4].
Herein we provide a current description of patterns and trends in
overall brain and CNS cancer incidence and mortality in Central and
South America, including incidence rates by histological type and
sex, which will provide a regional perspective and hopefully
contribute to some etiological clues about this disease in the region.
2. Material and methods
The present analysis includes brain and central nervous system
tumors (C70–C72) as coded by the 10th edition of the International
Classiﬁcation of Diseases for Oncology (ICD-10). Until the year
1991, the underlying cause of death was categorized according to
the ICD 9th revision; however, all data were converted to the ICD-
10th revision. The data sources and methods are described in detail
in an earlier article in this issue. In brief, we obtained regional- and
national-level incidence data from 48 population-based cancer
registries in 13 countries and cancer deaths from the World Health
Organization mortality database for 18 countries. We estimated
age-standardized incidence rates (ASRs) and mortality rates
(ASMRs) per 100,000 person-years using the direct method and
the World standard population [15,16]. We estimated national
ASRs by aggregating the data from the available cancer registries
using a weighted average of local rates. To describe incidence and
mortality time trends, we calculated the estimated annual
percentage change (EAPC) using the method proposed by Esteve
et al. [17]. Trends in incidence and EAPCs were estimated for only
four countries (Table 1) that provided written consent to use their
data or submitted new data for 10 years, and mortality data were
matched to the same time period to generate time trends and
EAPCs. All of the EAPCs were tested for equality to zero by using the
corresponding standard errors. We considered EAPCs statistically
signiﬁcant if the P-value  0.05. We conducted the data analysis in
Stata version 12.1 (StataCorp) [18].
In addition to the general methods described above, it is
important to draw attention to the inclusion of malignant
meningiomas (C70) in the analysis of this cancer site. Also, we
considered information by histological subtype as coded in ICD-O-
3; unspeciﬁed malignant neoplasms included all cases without
microscopical veriﬁcation in addition to cases classiﬁed asTable 1
Countries and cancer registries included in the analysis of time trends.
Country Name of registries included Period Coverage (%)
Argentina Bahia Blanca 1993–2007 0.8
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 1997–2006 8.0
Chile Valdivia 1993–2008 2.2
Costa Rica National registry 1985–2007 100.0unspeciﬁed, even with microscopical veriﬁcation. Despite their
clinical importance, benign tumors of the CNS were not included
given the existing variation regarding their inclusion among cancer
registries.
3. Results
Nearly 12,000 malignant brain and CNS tumors (6179 in males
and 5648 in females) were reported by the participating registries in
Central and South America in the time periods considered (Table 2).
3.1. Age-standardized incidence and mortality rates
There was considerable geographical variation in the incidence
and mortality of malignant brain and CNS tumors in Central and
South America. Males had incidence and mortality rates 10–50%
higher than those in females, with the exception of Bolivia
(incidence male-to-female ratio, M:F 0.4:1), and Suriname
(mortality M:F 0.8:1) (Table 2). In Central America, the highest
incidence ASRs among males and females were seen in Cuba (5.1
and 3.6, respectively) and Costa Rica (3.7 and 2.6), whereas the
lowest rates were in Mexico (2.7 and 2.5) and El Salvador (0.6 and
0.5). In South America, the highest incidence ASRs among males
and females were observed in Brazil (6.4 and 4.7) and Uruguay (6.2
and 4.0), while the lowest were in Chile (2.7 and 2.5) and Bolivia
(0.3 and 0.6). Mortality rates followed a pattern similar to
incidence rates (Table 2). Nevertheless, in several Central American
countries, as well as in Brazil and Suriname, brain and CNS cancers
ranked in the ﬁrst eight causes of cancer mortality among both
males and females (Table 2).
3.2. Age-speciﬁc incidence and mortality rates
Age-speciﬁc incidence rates (per 100,000) among males and
females followed a similar pattern in almost all Central and South
American countries, with rates peaking at two different stages. The
ﬁrst peak occurred at very young ages (0–5-year age group) and
slowly decreased until the age of 15 years followed by a renewed
and steady increase after the age of 25; the second peak occurred
after the age of 55 years (Figs. 1 and 2). The only country with a
slightly different pattern of age-speciﬁc incidence rates was El
Salvador where rates decreased between ages 25 and 45 and
slightly increased again; despite ﬂuctuations (probably due to
small numbers of cases) the rates were rather stable from age
50–65 years [1,2]. The age-speciﬁc mortality rates (per 100,000)
follow the same pattern as incidence rates.
3.3. Time trends
Trends in incidence and mortality rates in the four countries
evaluated showed remarkable ﬂuctuations over time; incidence
rates exhibited similar patterns between sexes, with the exception
of Chile (Fig. 3). In the most recent 10-year period, the largest
increases in brain and CNS cancer incidence were observed in
Argentinean males and females (EAPCs: 5.3 and 5.8, respectively,
P-value > 0.05) and Chilean males (EAPC: 5.1, P-value > 0.05)
whereas the largest declines in incidence occurred in Brazilian
and Costa Rican females (EAPC for both: 3.0, P > 0.05). The largest
increase in mortality was seen in Chilean females (EAPC: 3.3,
P > 0.05) while the highest declines were in Costa Rican females
(EAPC: 2.6, P > 0.05) (Fig. 4).
3.4. Histological types
The percentage of new cancer cases veriﬁed microscopically
(MV, shown in Table 2) was below 70% in Central American
Table 2
Brain and central nervous system cancers: incidence and mortality rates (per 100,000) in Central and South American countries.
Incidence Mortality
Country Period Sex Cases Crude rate ASR (W) Ranka M:F MV% Deaths Crude rate ASR (W) Ranka M:F
Central America
Belize 2003–07 M 12 1.7 2.6 7 1.2
F 12 1.7 2.2 10
Costa Rica 2003–07 M 359 3.3 3.7 13 1.4 70 289 2.6 3.0 9 1.5
F 260 2.5 2.6 15 68 197 1.9 2.0 11
Cubab 2004–07 M 106 6.5 5.1 10 1.4 65 1106 4.9 4.1 11 1.4
F 83 5.1 3.6 12 55 871 3.9 3.0 10
El Salvadorb 1999–2003 M 66 0.5 0.6 12 1.2 68 276 1.9 2.4 6 1.2
F 67 0.5 0.5 14 61 265 1.7 1.9 8
Guatemala 2003–07 M 548 1.8 2.5 6 1.1
F 533 1.6 2.2 7
Mexicob 2006–10 M 416 2.4 2.7 11 1.1 100 5223 1.9 2.5 10 1.4
F 413 2.3 2.5 12 100 4194 1.4 1.7 12
Nicaragua 2003–07 M 187 1.4 1.9 7 1.1
F 184 1.3 1.7 10
Panama 2003–07 M 225 2.8 3.0 7 1.1
F 214 2.7 2.8 8
South America
Argentinab 2003–07 M 644 5.2 5.3 15 1.1 66 2913 3.1 2.9 14 1.5
F 638 4.9 4.5 14 62 2372 2.4 1.9 12
Boliviab 2011 M 4 0.3 0.3 20 0.4 100
F 9 0.7 0.6 17 78
Brazilb 2003–07 M 3038 5.5 6.4 12 1.3 60 16337 3.6 4.0 7 1.2
F 2869 4.7 4.8 13 52 14984 3.2 3.2 5
Chileb 2003–07 M 58 2.5 2.7 17 1.1 52 809 2.0 2.0 14 1.4
F 56 2.5 2.5 18 46 662 1.6 1.4 15
Colombiab 2003–07 M 466 5.1 5.5 9 1.4 86 2667 2.5 3.1 8 1.3
F 399 4.0 3.9 13 80 2277 2.1 2.3 11
Ecuadorb 2003–07 M 176 3.7 4.2 11 1.2 88 637 1.9 2.2 8 1.1
F 170 3.3 3.4 15 83 587 1.8 1.9 10
French Guyanab 2003–08 M 18 3.6 4.8 12 2.3 89
F 8 1.6 2.1 19 88
Paraguay 2003–07 M 168 1.1 1.4 11 1.2
F 144 1.0 1.2 11
Perub 2001–05 M 390 4.2 4.5 10 1.3 73 1231 1.8 2.2 8 1.2
F 327 3.4 3.5 15 60 1067 1.6 1.8 11
Suriname 2003–07 M 28 2.2 2.7 6 0.8
F 42 3.4 3.4 6
Uruguay 2005–07 M 346 7.2 6.2 14.0 1.5 70 185 3.8 3.2 13 1.7
F 276 5.4 4.0 14.0 62 143 2.8 1.9 13
Venezuela 2003–07 M 1110 1.7 2.0 10 1.3
F 935 1.4 1.6 11
ASR (W), age-standardized (World population) rate per 100,000; M:F, male:female ratio; MV%: microscopical veriﬁcation.
a Rank based on highest ASR excluding: All sites but C44 and All sites.
b Incidence rates were estimated using aggregated data from regional cancer registries.
M. Piñeros et al. / Cancer Epidemiology 44S (2016) S141–S149 S143countries (with the exception of Mexico), while in South America it
ranged from 46% among women in Chile to 100% among men in
Bolivia (four cases).
The data included almost 12,000 incident cancers, of which
7342 (62.1%) were neuroepithelial tumors, and 3881 (32.8%) were
unspeciﬁed tumors (Table 3). Gliomas accounted for 55.4% of the
cases. Overall, 65% of the cancers had a microscopically veriﬁed
diagnosis; among unspeciﬁed malignant neoplasms, 7.7% had a
microscopically veriﬁed diagnosis. Thirteen per cent of the tumors
occurred in children (0–14 years), 58% in the 15–64-year age group
and 27% in the elderly (65+); 2% (data not shown) were lacking
information on age. The percentage of cancers was slightly higher
among males (52%) except for unspeciﬁed neoplasms (47.8%) and
“other speciﬁed” (40.8%) (Table 3).
Overall, the proportion of unspeciﬁed malignant neoplasm was
high and showed important variations between countries, being
highest among males in Chile (47%) and among females in Bolivia
(56%) (Table 4).
Within the neuroepithelial cancers, approximately 89% were
gliomas, 10% were embryonal tumors, and <1% were classiﬁed as
other. Astrocytic tumors were the most common gliomas amongboth males and females; in turn, medulloblastomas were the most
common type of embryonal tumors, accounting for 13% of all
neuroepithelial tumors (Table 5). The incidence rate of astrocytic
neoplasms in males ranged from 0.19 (in Bolivia) to 3.0 (in French
Guyana) and in females ranged from 0.24 (in Bolivia) to 2.0 (in
Ecuador). The incidence of oligodendroglial tumors was below
0.50, except for males and females in Uruguay (1.1 and 0.83,
respectively) and males in French Guyana (0.83). The incidence of
ependymal gliomas and embryonal tumors was also relatively low,
with rates <0.50 in males and <0.30 in females (Table 5).
4. Discussion
As in other regions of the world, in Central and South America
brain and CNS cancers represent a low burden; despite this, some
differences observed in the present study were noteworthy.
Overall, the burden (both in incidence and mortality) was more
prominent in Brazil, Colombia, Cuba and Uruguay than in the
remaining countries of the region. The highest incidence rates,
observed in Brazil, were comparable to the rates in the US and
other regions of the world; however, they were lower than the
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Fig. 1. Brain and CNS cancer: age-speciﬁc incidence and mortality rates among males in Central and South American countries.
S144 M. Piñeros et al. / Cancer Epidemiology 44S (2016) S141–S149incidence rates reported for the registry of Goiania, Brazil, among
men (10.5), which – together with Serbia (10.5), Sweden (9.5) and
Croatia (9.5) – are among the highest in the world [19]. With the
exception of Brazil, the incidence information from the other
aforementioned countries (Colombia, Cuba and Uruguay) was
provided exclusively by high-quality cancer registries (included in
the last volume of the serial IARC publication Cancer Incidence in
Five Continents), implying that the geographic variation in
incidence encountered between countries could represent a real
increased risk, although differences in diagnostic practices, case
ascertainments and healthcare access cannot be ruled out [5]. In
addition, for several countries the numbers included were verysmall given the rarity of these tumors; as such, differences in
geographical variation have to be interpreted with caution.
Both incidence and mortality rates of malignant brain and CNS
tumors were in general 10–50% higher among males than among
females, a ﬁnding that is consistent with the current literature [6].
An exception to this was Suriname, where mortality rates were
higher among females. The relatively high ranking in mortality
(among eight ﬁrst cancers) found in several countries, among
them Suriname, Brazil and several Central American countries,
needs to be interpreted with caution given the possibility of
suboptimal coverage of the civil registration system in those
countries [20].
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Fig. 2. Brain and CNS cancer: age-speciﬁc incidence and mortality rates among females in Central and South American countries.
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observed in Argentina and Chile should be followed up closely.
Similarly, though increasing mortality trends in Argentina, Brazil
and Costa Rica were not statistically signiﬁcant, a previous
Brazilian study documented an overall increase of 50% in brain
and CNS tumor mortality in Brazil between 1980 and 81 and 1996–
97 (2.2 per 100,000 to 3.4 per 100,000, respectively) [13]. Similarly,
in Colombia, signiﬁcantly increasing mortality trends have also
been documented among males and females with EAPCs of 3.0 and
3.4, respectively [14].
Explaining the observed geographic variation and sex disparity
in brain and CNS tumors is challenging, as not only are under-ascertainment and under-reporting possible contributing reasons,
but also because the etiology of these tumors is still poorly
understood [9]. The only known causative factor for brain and CNS
tumors is exposure to ionizing radiation [21]; high doses of
therapeutic radiation have been linked with an increased risk of
brain and CNS tumors [3,6,10,12,22], although their prevalence in
the general population is low.
One of the worst radiological accidents in the western
hemisphere occurred in Goiania (Brazil) in 1987 with caesium-
137 [23,24], and a study performed 20 years later of offspring of
irradiated parents in the same city revealed that the mutation rates
among exposed families where higher than in non-exposed
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S146 M. Piñeros et al. / Cancer Epidemiology 44S (2016) S141–S149families from the same area [25]. These ﬁndings suggest the need
for a more detailed epidemiological study on this topic to provide
better insights into possible associations, particularly given the
high brain and CNS cancer incidence rates in that area.
Although not consistently, farming and occupational exposure
to pesticides have been associated with an increased risk of brain
and CNS tumors [26–28] and might be an important aspect to
study further in the region; preliminary studies performed in-10 
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Fig. 4. Estimated annual percentage change in age-standardized brain Brazil have shown an increased risk of brain and CNS cancer
mortality related to pesticide exposures [29,30]. Agriculture is an
important economic activity in the region [31,32] and the use of
pesticides for agricultural purposes has increased, being particu-
larly high in Colombia, Bolivia and Ecuador [33]. As such, exposure
to pesticides constitutes an important topic for further research
that might explain the geographic variation and sex gap if
association with brain and CNS cancers is clariﬁed.2.1
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Table 3
Characteristics of brain and CNS cancers by histological groups and age group.
Age at diagnosis (%)
Total MV (%) Male (%) 0–14 15–64 65+
Gliomas
Astrocytic 5119 94.0 55.1 7 65 25
Oligodendroglial 639 98.4 57.0 5 81 12
Ependymal 340 97.1 54.1 40 53 4
Others 451 70.7 53.4 29 49 20
Embryonal
Medulloblastoma 556 97.5 60.4 63 35 1
Other 210 95.2 53.8 54 36 6
Other neuroepithelial 27 33.3 70.4 52 44 4
Other speciﬁed 603 93.9 40.8 8 63 28
Unspeciﬁed malignant neoplasm 3881 7.7 47.8 9 51 39
All 11,826 65.3 52.2 13 58 27
M. Piñeros et al. / Cancer Epidemiology 44S (2016) S141–S149 S147While the overall percentage of gliomas encountered (55%) was
similar to the percentage reported by Hoffman et al. in the US, the
percentage of unspeciﬁed cancers in our study was remarkable
high and contrasts strongly with their 3.6% [11]. This undoubtedly
limits the interpretation of rates by histological type in the region.
The vast majority of unspeciﬁed tumors had no microscopical
veriﬁcation; nevertheless, a non-negligible percentage of unspeci-
ﬁed cases (almost 8%) had a microscopically veriﬁed diagnosis,
implying clearly the existence of difﬁculties in the classiﬁcation of
these tumors by pathologists, a fact that has been recognized
among the specialized community [34]. Large variations were
observed between countries regarding the percentage of MV cases.
In Mexico, where only one cancer registry participated, 100% of theTable 4
Age-standardized (World population) incidence rates per 100,000 of brain and CNS ca
Tumours of neuroepithelial tissue 
n (%) ASR 
Males
Argentinaa (2003–2007) 381 (59) 3.2 
Boliviaa (2011) 4 (100) 0.27 
Brazila (2003–2007) 1782 (59) 3.7 
Chilea (2003–2007) 24 (41) 1.2 
Colombiaa (2003–2007) 349 (75) 4.1 
Costa Rica (2003–2007) 239 (67) 2.4 
Cubaa (2004–2007) 49 (46) 2.9 
Ecuadora (2003–2007) 152 (86) 3.6 
El Salvadora (1999–2003) 56 (85) 0.5 
French Guyanaa (2003–2007) 16 (89) 4.4 
Mexicoa (2006–2010) 457 (90) 2.5 
Perua (2001–2005) 320 (82) 3.7 
Uruguay (2005–2007) 247 (71) 4.6 
Females
Argentinaa (2003–2007) 322 (50) 2.5 
Boliviaa(2011) 4 (44) 0.29 
Brazila (2003–2007) 1426 (50) 2.4 
Chilea (2003–2007) 22 (39) 1.1 
Colombiaa (2003–2007) 259 (65) 2.6 
Costa Rica (2003–2007) 169 (65) 1.7 
Cubaa(2004–2007) 34 (41) 1.7 
Ecuadora (2003–2007) 131 (77) 2.7 
El Salvador (1999–2003) 57 (85) 0.44 
French Guyanaa (2003–2007) 7 (88) 1.9 
Mexicoa (2006–2010) 429 (88) 2.2 
Perua (2001–2005) 243 (74) 2.6 
Uruguay (2005–2007) 163 (59) 2.8 
ASR, age-standardized (World population) incidence rates; n, number of incident cases
a Incidence rates were estimated using aggregated data from regional cancer registrbrain and CNS cancers were microscopically veriﬁed, indicating a
registry that over-relies on pathology information sources. The
overall percentage of MV cases in several Central and South
American countries was between 50 and 60%, lower than the MV
percentages reported in the US (i.e. close to 90% for brain and CNS
tumors diagnosed in persons under the age of 65 years, and 80% for
persons aged 75–84 years) [35].
While the incidence rates of astrocytic tumors observed in most
countries in the Central and South American region was lower than
that reported in Europe (4.8 per 100,000) [8], the observed
incidence rates of medulloblastoma among males in Cuba (0.47),
Peru (0.43) and Uruguay (0.41) were higher than the incidencencers by major histological groups, sex and country.
Other speciﬁed Unspeciﬁed malignant neoplasm
n (%) ASR n (%) ASR
52 (8) 0.42 211 (33) 1.7
0 (0) – 0 (0) –
68 (2) 0.14 1188 (39) 2.6
7 (12) 0.30 27 (47) 1.2
17 (4) 0.21 100 (21) 1.2
5 (1) 0.04 115 (32) 1.2
14 (13) 0.57 43 (41) 1.6
5 (3) 0.12 19 (11) 0.49
3 (5) 0.02 7 (11) 0.07
1 (6) 0.23 1 (6) 0.22
50 (10) 0.28 0 (0) –
11 (3) 0.12 59 (15) 0.68
13 (4) 0.21 86 (25) 1.4
98 (15) 0.69 218 (34) 1.4
0 (0) – 5 (56) 0.35
95 (3) 0.16 1348 (47) 2.2
7 (13) 0.31 27 (48) 1.2
41 (10) 0.41 99 (25) 0.93
1 (0) 0.01 90 (35) 0.89
7 (8) 0.38 42 (51) 1.6
14 (8) 0.29 25 (15) 0.48
1 (1) 0.01 9 (13) 0.07
1 (13) 0.27 0 (0) –
57 (12) 0.30 0 (0) –
14 (4) 0.15 70 (21) 0.74
21 (8) 0.30 92 (33) 0.91
.
ies.
Table 5
Age-standardized incidence rates (per 100,000) of malignant neuroepithelial tissue tumors, by histological subtype, sex and country.
Gliomas Embryonal tumors Other neuroepithelial
Astrocytic Oligodendroglial Ependymal Others Medulloblastoma Other
n (%) ASR n (%) ASR n (%) ASR n (%) ASR n (%) ASR n (%) ASR n (%) ASR
MALES
Argentinaa (2003–07) 264 (69) 2.2 34 (9) 0.27 25 (7) 0.22 8 (2) 0.07 35 (9) 0.31 13 (3) 0.12 2 (<1) 0.02
Boliviaa (2011) 3 (75) 0.19 1 (25) 0.08 0 (0) – 0 (0) – 0 (0) – 0 (0) – 0 (0) –
Brazila (2003–07) 1314 (74) 2.8 102 (6) 0.18 79 (4) 0.15 97 (5) 0.19 129 (7) 0.23 49 (3) 0.09 12 (1) 0.03
Chilea (2003–07) 15 (63) 0.73 2 (8) 0.10 1 (4) 0.06 1 (4) 0.04 2 (8) 0.13 3 (13) 0.18 0 (0) –
Colombiaa (2003–07) 234 (67) 2.8 39 (11) 0.44 19 (5) 0.22 18 (5) 0.22 26 (8) 0.29 10 (3) 0.13 3 (1) 0.03
Costa Rica (2003–07) 144 (60) 1.5 40 (17) 0.37 13 (5) 0.13 8 (3) 0.07 25 (10) 0.24 9 (4) 0.09 0 (0) –
Cubaa (2004–07) 36 (73) 1.9 4 (8) 0.19 2 (4) 0.17 2 (4) 0.18 5 (10) 0.47 0 (0) – 0 (0) –
Ecuadora (2003–07) 102 (67) 2.5 23 (15) 0.50 5 (3) 0.10 11 (7) 0.29 11 (7) 0.21 0 (0) – 0 (0) –
El Salvadora (1999–03) 36 (64) 0.34 6 (11) 0.06 2 (4) 0.02 5 (9) 0.04 5 (9) 0.03 2 (4) 0.01 0 (0) –
French Guyanaa (2003–07) 10 (63) 3.0 3 (19) 0.83 1 (6) 0.20 2 (13) 0.40 0 (0) – 0 (0) – 0 (0) –
Mexicoa (2006–10) 321 (70) 1.8 23 (5) 0.12 21 (5) 0.11 26 (6) 0.14 43 (9) 0.21 21 (5) 0.12 2 (<1) 0.01
Perua (2001–05) 223 (70) 2.5 27 (8) 0.33 6 (2) 0.08 21 (7) 0.24 38 (12) 0.43 5 (2) 0.05 0 (0) –
Uruguay (2005–07) 117 (47) 2.1 60 (24) 1.1 10 (4) 0.22 42 (17) 0.75 17 (7) 0.41 1 (0) 0.02 0 (0) –
FEMALES
Argentinaa (2003–07) 226 (70) 1.7 32 (10) 0.24 26 (8) 0.23 7 (2) 0.04 21 (7) 0.19 10 (3) 0.09 0 (0) –
Boliviaa (2011) 3 (75) 0.24 1 (25) 0.06 0 (0) – 0 (0) – 0 (0) – 0 (0) – 0 (0) –
Brazila (2003–07) 1061 (74) 1.8 96 (7) 0.15 59 (4) 0.10 75 (5) 0.13 95 (7) 0.17 34 (2) 0.07 6 ( < 1) 0.01
Chilea (2003–07) 13 (59) 0.62 2 (9) 0.09 0 (0) – 2 (9) 0.09 2 (9) 0.11 3 (14) 0.15 0 (0) –
Colombiaa (2003–07) 187 (72) 1.9 19 (7) 0.17 14 (5) 0.14 16 (6) 0.15 15 (6) 0.18 8 (3) 0.08 0 (0) –
Costa Rica (2003–07) 105 (62) 1.1 23 (14) 0.21 11 (7) 0.12 6 (4) 0.06 17 (10) 0.17 7 (4) 0.07 0 (0) –
Cubaa (2004–07) 23 (68) 1.1 7 (21) 0.38 2 (6) 0.12 1 (3) 0.06 0 (0) – 0 (0) – 1 (3) 0.04
Ecuadora (2003–07) 96 (73) 2.0 10 (8) 0.17 5 (4) 0.10 8 (6) 0.17 11 (8) 0.25 1 (1) 0.03 0 (0) –
El Salvadora (1999–03) 39 (68) 0.31 7 (12) 0.05 1 (2) 0.01 8 (14) 0.06 2 (4) 0.01 0 (0) – 0 (0) –
French Guyanaa (2003–07) 4 (57) 1.3 0 (0) – 0 (0) – 1 (14) 0.17 1 (14) 0.17 1 (14) 0.19 0 (0) –
Mexicoa (2006–10) 313 (73) 1.6 17 (4) 0.08 18 (4) 0.09 26 (6) 0.13 31 (7) 0.15 24 (6) 0.12 0 (0) –
Perua (2001–05) 167 (69) 1.8 11 (5) 0.10 14 (6) 0.14 29 (12) 0.31 15 (6) 0.18 7 (3) 0.06 0 (0) –
Uruguay (2005–07) 63 (39) 1.0 50 (31) 0.83 6 (4) 0.11 31 (19) 0.54 10 (6) 0.24 2 (1) 0.05 1 (<1) 0.02
n, number of incident cases; ASR, age-standardized (World population) rate per 100,000.
a Incidence rates were estimated using aggregated data from regional cancer registries.
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ranging between 0.2 and 0.3 [19].
This study presents the most comprehensive description of
brain and CNS cancer incidence and mortality rates in Central and
South America; however, data patterns must be interpreted with
caution due to the absence of national data (except for Costa Rica
and Uruguay) and low coverage of the included regional registries.
Incidence rates are probably underestimated, especially by
histological type, given the high percentage of unspeciﬁed
malignant incident neoplasms. There is a potential for misclassiﬁ-
cation of these malignancies due to the complexities in the tumor’s
pathological classiﬁcation [34]. Hence, there is a need to improve
the ascertainment of cases and to improve the accuracy of
diagnosis to minimize inter-observer variability among different
pathologists in the region, particularly after the introduction of the
new brain and CNS tumor classiﬁcation of 2007 [1].
The sparse data available about the descriptive and analytical
epidemiology of these tumors in the Central and South American
region opens the opportunity for collaborative research that could
contribute to an improvement in the quality of diagnosis as well as
to better knowledge on the burden (incidence, mortality, preva-
lence, survival) of these malignancies and the prevalence of
relevant risk factors, similarly to the groups established in Europe
[8,36], the United States and Canada [37–39].
5. Conclusion
Despite the fact that brain and CNS cancers are rare in Central
and South America, noticeable geographic variations and sex
disparity in incidence and mortality rates were observed. Higher
rates were observed in the only two countries that have national
registration, pointing out differences in case ascertainment
between registries, reporting of cases and diagnostic practices.Interpretation of data patterns is also complex given that the
etiology of this malignancy is largely unknown; radiation
exposure, the only established risk factor, probably contributed
very little to the variations observed given the low prevalence in
the general population. However, the extent to which other
putative exposures contributed to the variations are yet to be
known. It is therefore likely that the descriptive epidemiology of
brain and CNS tumors would continue to provide clues about the
complex etiology of this malignancy. As such, careful monitoring of
brain and CNS cancers along with etiological research remain
priorities.
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